{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:59:58Z","timestamp":1790722798317,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.semarthrit.2026.153083","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:16:08Z","timestamp":1790205368000},"page":"153083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Glucocorticoid discontinuation in patients with rheumatoid arthritis who initiated biologic or targeted synthetic agents: a real-world population-based analysis"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8496-2172","authenticated-orcid":false,"given":"Yingzhao","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-0995","authenticated-orcid":false,"given":"Steven H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5074-2948","authenticated-orcid":false,"given":"Isaac T","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6410-8852","authenticated-orcid":false,"given":"Lai-shan","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.semarthrit.2026.153083_bib0001","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Collaborators GBDRA: global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"10055","key":"10.1016\/j.semarthrit.2026.153083_bib0002","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153083_bib0003","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/annrheumdis-2013-204788","article-title":"Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial","volume":"73","author":"de Jong","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153083_bib0004","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/annrheumdis-2013-205143","article-title":"Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial","volume":"74","author":"ter Wee","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153083_bib0005","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2012-202333","article-title":"Allaart CF: meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis","volume":"72","author":"Boers","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153083_bib0006","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/annrheumdis-2020-219825","article-title":"Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial","volume":"80","author":"Stouten","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153083_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153083_bib0008","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1136\/annrheumdis-2016-210135","article-title":"Combe B: seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort","volume":"76","author":"Roubille","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153083_bib0009","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/acr2.11334","article-title":"A bridge too far? Real-world practice patterns of early glucocorticoid use in the Canadian early arthritis cohort","volume":"4","author":"Andersen","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153083_bib0010","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/annrheumdis-2021-220112","article-title":"Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020","volume":"80","author":"Xie","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153083_bib0011","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1093\/rheumatology\/keaa850","article-title":"Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis","volume":"60","author":"Roubille","year":"2021","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153083_bib0012","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/keu339","article-title":"Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice","volume":"54","author":"Fortunet","year":"2015","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.153083_bib0013","first-page":"807","article-title":"Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice","volume":"27","author":"Seror","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153083_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152314","article-title":"Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: australia wide study","volume":"64","author":"Scheepers","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153083_bib0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/rheumatology\/keae077","article-title":"Very-low-dose glucocorticoid therapy in rheumatoid arthritis: impact of b\/tsDMARDs initiation timing on glucocorticoid withdrawal","volume":"64","author":"Giollo","year":"2025","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153083_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105671","article-title":"Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: results from the international TOCERRA and PANABA observational collaborative studies","volume":"91","author":"Lauper","year":"2024","journal-title":"Jt Bone Spine"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153083_bib0017","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/ard-2022-223443","article-title":"Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis","volume":"82","author":"van Ouwerkerk","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153083_bib0018","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/annrheumdis-2022-222338","article-title":"Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis","volume":"81","author":"van Ouwerkerk","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153083_bib0019","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard-2023-224185","article-title":"Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study","volume":"82","author":"So","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153083_bib0020","article-title":"Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis","volume":"4","author":"Wong","year":"2022","journal-title":"JHEP Rep"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153083_bib0021","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2026.153083_bib0022","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.ard.2026.01.023","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update","volume":"85","author":"Smolen","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153083_bib0023","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ard-2023-224270","article-title":"Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?","volume":"83","author":"van Ouwerkerk","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153083_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152305","article-title":"Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis","volume":"64","author":"van Ouwerkerk","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153083_bib0025","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1093\/rheumatology\/kead088","article-title":"Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis","volume":"62","author":"Palmowski","year":"2023","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153083_bib0026","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/M20-1594","article-title":"Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis : a cohort study","volume":"173","author":"George","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153083_bib0027","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/rheumatology\/keae455","article-title":"Glucocorticoid sparing effect of Janus kinase inhibitors compared to biologic disease modifying anti-rheumatic drugs in rheumatoid arthritis, a single-centre retrospective analysis","volume":"64","author":"Adami","year":"2025","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153083_bib0028","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf552","article-title":"Clinical efficacy of JAK inhibitors for rheumatoid arthritis patients with poor-prognosis factors: the ANSWER cohort study","volume":"65","author":"Nozaki","year":"2026","journal-title":"Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153083_bib0029","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf612","article-title":"The impact of glucocorticoids on the efficacy of JAK inhibitors or non-TNF-targeted biologics in rheumatoid arthritis","volume":"65","author":"Salvato","year":"2026","journal-title":"Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153083_bib0030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","article-title":"The Jak\/STAT pathway: a focus on pain in rheumatoid arthritis","volume":"51","author":"Simon","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.153083_bib0031","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume":"Volume 13","author":"Harrington","year":"2020","journal-title":"J Inflamm Res"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153083_bib0032","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.43014","article-title":"Effectiveness of JAK inhibitors compared with biologic disease-modifying antirheumatic drugs on pain reduction in rheumatoid arthritis: results from a nationwide Swedish cohort study","volume":"77","author":"Eberhard","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153083_bib0033","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3390\/ijms23031246","article-title":"Janus kinase inhibitors improve disease activity and patient-reported outcomes in rheumatoid arthritis: a systematic review and meta-analysis of 24,135 patients","volume":"23","author":"Toth","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153083_bib0034","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:08:20Z","timestamp":1790719700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226001733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":34,"alternative-id":["S0049017226001733"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153083","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucocorticoid discontinuation in patients with rheumatoid arthritis who initiated biologic or targeted synthetic agents: a real-world population-based analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"153083"}}